<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">941</article-id><article-id pub-id-type="doi">10.17650/2222-1468-2023-13-4-92-100</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Low expression of the <italic>ST6GAL2</italic> and <italic>CD248</italic> genes as an unfavorable prognostic marker of oral squamous cell carcinoma</article-title><trans-title-group xml:lang="ru"><trans-title>Низкая экспрессия генов <italic>ST6GAL2</italic> и <italic>CD248</italic> как неблагоприятный прогностический маркер плоскоклеточной карциномы полости рта</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7540-8532</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedorova</surname><given-names>I. K.</given-names></name><name xml:lang="ru"><surname>Федорова</surname><given-names>И. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>634009; 5 Kooperativny Line; Tomsk</p></bio><bio xml:lang="ru"><p>Ирина Казановна Федорова</p><p>634009; пер. Кооперативный, 5; Томск</p></bio><email>irina_fedorova96@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9122-3274</contrib-id><name-alternatives><name xml:lang="en"><surname>Kolegova</surname><given-names>E. S.</given-names></name><name xml:lang="ru"><surname>Колегова</surname><given-names>Е. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>634009; 5 Kooperativny Line; Tomsk</p></bio><bio xml:lang="ru"><p>634009; пер. Кооперативный, 5; Томск</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1405-3723</contrib-id><name-alternatives><name xml:lang="en"><surname>Prostakishina</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Простакишина</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>634009; 5 Kooperativny Line; Tomsk</p></bio><bio xml:lang="ru"><p>634009; пер. Кооперативный, 5; Томск</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8770-3117</contrib-id><name-alternatives><name xml:lang="en"><surname>Dampilova</surname><given-names>T. D.</given-names></name><name xml:lang="ru"><surname>Дампилова</surname><given-names>Т. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>634009; 5 Kooperativny Line; Tomsk</p></bio><bio xml:lang="ru"><p>634009; пер. Кооперативный, 5; Томск</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2865-7576</contrib-id><name-alternatives><name xml:lang="en"><surname>Patysheva</surname><given-names>M. R.</given-names></name><name xml:lang="ru"><surname>Патышева</surname><given-names>М. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>634009; 5 Kooperativny Line; Tomsk</p></bio><bio xml:lang="ru"><p>634009; пер. Кооперативный, 5; Томск</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0646-6093</contrib-id><name-alternatives><name xml:lang="en"><surname>Yamshchikov</surname><given-names>P. S.</given-names></name><name xml:lang="ru"><surname>Ямщиков</surname><given-names>П. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>634009; 5 Kooperativny Line; Tomsk</p></bio><bio xml:lang="ru"><p>634009; пер. Кооперативный, 5; Томск</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2923-9755</contrib-id><name-alternatives><name xml:lang="en"><surname>Denisov</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Денисов</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>634009; 5 Kooperativny Line; Tomsk</p></bio><bio xml:lang="ru"><p>634009; пер. Кооперативный, 5; Томск</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3651-0665</contrib-id><name-alternatives><name xml:lang="en"><surname>Choynzonov</surname><given-names>E. L.</given-names></name><name xml:lang="ru"><surname>Чойнзонов</surname><given-names>Е. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>634009; 5 Kooperativny Line; Tomsk</p></bio><bio xml:lang="ru"><p>634009; пер. Кооперативный, 5; Томск</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3089-5047</contrib-id><name-alternatives><name xml:lang="en"><surname>Kulbakin</surname><given-names>D. E.</given-names></name><name xml:lang="ru"><surname>Кульбакин</surname><given-names>Д. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>634009; 5 Kooperativny Line; Tomsk</p></bio><bio xml:lang="ru"><p>634009; пер. Кооперативный, 5; Томск</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Cancer Research Institute of Tomsk National Research Medical Center of the Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт онкологии ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-12-30" publication-format="electronic"><day>30</day><month>12</month><year>2023</year></pub-date><volume>13</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>92</fpage><lpage>100</lpage><history><date date-type="received" iso-8601-date="2024-04-06"><day>06</day><month>04</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-04-06"><day>06</day><month>04</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Fedorova I.K., Kolegova E.S., Prostakishina E.A., Dampilova T.D., Patysheva M.R., Yamshchikov P.S., Denisov E.V., Choynzonov E.L., Kulbakin D.E.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Федорова И.К., Колегова Е.С., Простакишина Е.А., Дампилова Т.Д., Патышева М.Р., Ямщиков П.С., Денисов Е.В., Чойнзонов Е.Л., Кульбакин Д.Е.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Fedorova I.K., Kolegova E.S., Prostakishina E.A., Dampilova T.D., Patysheva M.R., Yamshchikov P.S., Denisov E.V., Choynzonov E.L., Kulbakin D.E.</copyright-holder><copyright-holder xml:lang="ru">Федорова И.К., Колегова Е.С., Простакишина Е.А., Дампилова Т.Д., Патышева М.Р., Ямщиков П.С., Денисов Е.В., Чойнзонов Е.Л., Кульбакин Д.Е.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/941">https://ogsh.abvpress.ru/jour/article/view/941</self-uri><abstract xml:lang="en"><p><bold>   Introduction. </bold>Squamous cell carcinoma (SCC) of the oral cavity is an aggressive and rapidly progressing disease. The tendency to progression of the tumor process is due to the clinical and pathological characteristics of the patient and the biological characteristics of the tumor. molecular and genetic disorders related with transcriptome level play an important role in tumor progression, which can be used in predicting the outcome of the disease.</p><p><bold>   Aim. </bold>To identify markers for assessing the risk of the SCC progression.</p><p><bold>   Materials and methods. </bold>Based on the data of the Cancer genome Atlas database, a bioinformatic search for genes associated with the progression of SCC was performed (11 genes were selected). Then we performed a retrospective analysis of clinical data and histological material from 38 patients with SCC treated at the Scientific Research Institute of Oncology of the Tomsk National Research medical Center of the Russian Academy of Sciences from 2018 to 2021. Fixed samples of tumor tissue were examined. The level of gene expression was determined by real-time quantitative polymerase chain reaction.</p><p><bold>   Results.</bold> It was shown that decrease in the ST6GAL2 matrix RNA level is associated with presence of lymphogenic metastases and decrease in the CD248 matrix RNA level is associated with the occurrence of relapses.</p><p><bold>   Conclusion.</bold> Expression level of the ST6GAL2 and CD248 genes can be used as predictors of an unfavorable prognosis of SCC.</p></abstract><trans-abstract xml:lang="ru"><p><bold>   Введение. </bold>Плоскоклеточная карцинома полости рта (ПКПР) является агрессивным и быстропрогрессирующим заболеванием. Склонность к прогрессированию опухолевого процесса обусловлена клинико-патологическими характеристиками больного и биологическими особенностями опухоли. Большую роль в прогрессии опухоли имеют молекулярно-генетические нарушения, отражающиеся на транскриптомном уровне, что может быть использовано в прогнозе исхода заболевания.</p><p><bold>   Цель исследования</bold> – выявить маркеры для оценки риска прогрессирования ПКПР.</p><p><bold>   Материалы и методы. </bold>На основании данных базы «Атлас ракового генома» (The Cancer genome Atlas, TCGA) проведен биоинформатический поиск генов, ассоциированных с прогрессией ПКПР (отобраны 11 генов). Затем выполнен ретроспективный анализ клинических данных и гистологического материала 38 больных ПКПР, проходивших лечение в Научно-исследовательском институте онкологии ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук» с 2018 по 2021 гг. Исследовались фиксированные образцы опухолевой ткани. Уровень экспрессии генов определялся методом количественной полимеразной цепной реакции в режиме реального времени.</p><p><bold>   Результаты. </bold>Показано, что снижение уровня матричной РНК ST6GAL2 связано с наличием лимфогенных метастазов, а уменьшение уровня матричной РНК CD248 – с возникновением рецидивов.</p><p><bold>   Заключение. </bold>Уровень экспрессии генов ST6GAL2 и CD248 может использоваться в качестве предикторов неблагоприятного прогноза ПКПР.</p></trans-abstract><kwd-group xml:lang="en"><kwd>squamous cell oral carcinoma, ST6GAL2, CD248, tumor progression, The Cancer genome Atlas</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>плоскоклеточная карцинома полости рта</kwd><kwd>ST6GAL2</kwd><kwd>CD248</kwd><kwd>прогрессия опухоли</kwd><kwd>«Атлас ракового генома»</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The work was carried out with the financial support of the Russian Science Foundation (grant No. 23-75-01157)</funding-statement><funding-statement xml:lang="ru">Работа выполнена при финансовой поддержке Российского научного фонда (грант № 23-75-01157)</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Wu K., Jiang Y., Zhou W. et al. Long noncoding RNA RC3H2 facilitates cell proliferation and invasion by targeting microRNA-101-3p/EZH2 axis in OSCC. Mol Ther Nucleic Acids 2020;20: 97–110. DOI: 10.1016/j.omtn.2020.02.006</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6): 394–424. DOI: 10.3322/caac.21492</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Zanoni D.K., Montero P.H., Migliacci J.C. et al. Survival outcomes after treatment of cancer of the oral cavity (1985–2015). Oral Oncol 2019;90:115–21. DOI: 10.1016/j.oraloncology.2019.02.001</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Weckx A., Riekert M., Grandoch A. et al. Time to recurrence and patient survival in recurrent oral squamous cell carcinoma. Oral Oncol 2019;94:8–13. DOI: 10.1016/j.oraloncology.2019.05.002</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Safi A.F., Kauke M., Grandoch A. et al. Analysis of clinicopathological risk factors for locoregional recurrence of oral squamous cell carcinoma – retrospective analysis of 517 patients. J Craniomaxillofac Surg 2017;45(10):1749–53. DOI: 10.1016/j.jcms.2017.07.012</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bugshan A., Farooq I. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Res 2020;9:229. DOI: 10.12688/f1000research.22941.1</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kleverov M., Zenkova D., Kamenev V. et al. Phantasus: web-application for visual and interactive gene expression analysis. BioRxiv 2022;12. DOI: 10.1101/2022.12.10.519861</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Arriaga J.M., Bravo A.I., Mordoh J., Bianchini M. Metallothionein 1G promotes the differentiation of HT-29 human colorectal cancer cells. Oncol Rep 2017;37(5):2633–51. DOI: 10.3892/or.2017.5547</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zhang M., Chai Y.D., Brumbaugh J. et al. Oral cancer cells may rewire alternative metabolic pathways to survive from siRNA silencing of metabolic enzymes. BMC Cancer 2014;14:223. DOI: 10.1186/1471-2407-14-223</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kontsekova S., Polcicova K., Takacova M., Pastorekova S. Endosialin: molecular and functional links to tumor angiogenesis. Neoplasma 2016;63(2):183–92. DOI: 10.4149/202_15090N474</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Rettig W.J., Garin-Chesa P., Healey J.H. et al. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 1992;89(22):10832–6. DOI: 10.1073/pnas.89.22.10832</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>St Croix B., Rago C., Velculescu V. et al. Genes expressed in human tumor endothelium. Science 2000;289(5482):1197–202. DOI: 10.1126/science.289.5482.1197</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Zhao X.T., Zhu Y., Zhou J.F. et al. Development of a novel 7 immune-related genes prognostic model for oral cancer: A study based on TCGA database. Oral Oncol 2021;112:105088. DOI: 10.1016/j.oraloncology.2020.105088</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hedlund M., Ng E., Varki A., Varki NM. Alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res 2008;68(2):388–94. DOI: 10.1158/0008-5472.CAN-07-1340</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Nakano M., Saldanha R., Göbel A. et al. Identification of glycan structure alterations on cell membrane proteins in desoxyepothilone B resistant leukemia cells. Mol Cell Proteomics 2011;10(11):M111.009001. DOI: 10.1074/mcp.M111.009001</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Liang L., Xu J., Wang M. et al. LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge. Cell Death Dis 2018;9(3):372. DOI: 10.1038/s41419-018-0382-7</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Agrawal P., Fontanals-Cirera B., Sokolova E. et al. A systems biology approach identifies FUT8 as a driver of melanoma metastasis. Cancer Cell 2017;31(6):804–19.e7. DOI: 10.1016/j.ccell.2017.05.007</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wu T., Jiao Z., Li Y. et al. HPRT1 Promotes chemoresistance in oral squamous cell carcinoma via activating MMP1/PI3K/Akt signaling pathway. Cancers (Basel) 2022;14(4):855. DOI: 10.3390/cancers14040855</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Ye H., Zheng Z., Song Y. et al. Metabolism-related bioinformatics analysis reveals that HPRT1 Facilitates the progression of oral squamous cell carcinoma in vitro. J Oncol 2022;2022:7453185. DOI: 10.1155/2022/7453185</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Guo Q., Zhang Q., Lu L., Xu Y. Long noncoding RNA RUSC1-AS1 promotes tumorigenesis in cervical cancer by acting as a competing endogenous RNA of microRNA-744 and conse-quently increasing Bcl-2 expression. Cell Cycle 2020;19(10):1222–35. DOI: 10.1080/15384101.2020.1749468</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Zou D., Lou J., Ke J. et al. Integrative expression quantitative trait locus-based analysis of colorectal cancer identified a functional polymorphism regulating SLC22A5 expression. Eur J Cancer 2018;93:1–9. DOI: 10.1016/j.ejca.2018.01.065</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Yang Y., Wu J., Yu X. et al. SLC34A2 promotes cancer proliferation and cell cycle progression by targeting TMPRSS3 in colorectal cancer. Pathol Res Pract 2022;229:153706. DOI: 10.1016/j.prp.2021.153706</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Zhang H.X., Liu O.S., Deng C. et al. Genome-wide gene expression profiling of tongue squamous cell carcinoma by RNA-seq. Clin Oral Investig 2018;22(1):209–16. DOI: 10.1007/s00784-017-2101-7</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Almhöjd U., Cevik-Aras H., Karlsson N. et al. Stimulated saliva composition in patients with cancer of the head and neck region. BMC Oral Health 2021;21(1):509. DOI: 10.1186/s12903-021-01872-x</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ghantous Y., Bahouth Z., Abu El-Naaj I. Clinical and genetic signatures of local recurrence in oral squamous cell carcinoma. Arch Oral Biol 2018;95:141–8. DOI: 10.1016/j.archoralbio.2018.07.018</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Jadhav K.B., Gupta N. Clinicopathological prognostic implicators of oral squamous cell carcinoma: need to understand and revise. N Am J Med Sci 2013;5(12):671–9. URL: https://www.researchgate.net/publication/259632012_Clinicopathological_Prognostic_Implicators_of_Oral_Squamous_Cell_Carcinoma_Need_to_Understand_and_Revise</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Milflores-Flores L., Millán-Pérez L., Santos-López G. et al. Characterization of P1 promoter activity of the beta-galactoside alpha2,6-sialyltransferase I gene (siat 1) in cervical and hepatic cancer cell lines. J Biosci 2012;37(2):259–67. DOI: 10.1007/s12038-012-9194-6</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>McGreal E.P., Ikewaki N., Akatsu H. et al. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J Immunol 2002;168(10):5222–32. DOI: 10.4049/jimmunol.168.10.5222</mixed-citation></ref></ref-list></back></article>
